Diagnostic technique for undifferentiated connective tissue dysplasia in females with personal history of miscarriage
SUBSTANCE: invention concerns diagnosing undifferentiated connective tissue dysplasia (UCTD) in females with a personal history of miscarriage. The technique involves determining the fibrinolytic activity in an endometrial biopsy sample. If the value is less than 23.55 mm2, undifferentiated connective tissue dysplasia is diagnosed.
EFFECT: invention provides the high diagnostic accuracy and enables diagnosing UCTD in the females with the personal history of early miscarriage.
2 tbl, 2 ex
The invention relates to medicine, namely to obstetrics and gynecology.
Women define fibrinolytic activity (FA) in endometrial biopsy method fibrin plates, and when the indicators F below 23,55 mm2diagnosed undifferentiated connective tissue dysplasia (NDCT) with efficiency of 92.6% (Method, based on fibrin plates (the determination of the activity of plasmin and plasminogen activator) by T. Astrup, S. Mullertz, 1952).
The problem of loss of pregnancy continues to maintain its relevance and priority in modern obstetrics. This is due primarily to the fact that the loss of a pregnancy is one of the main components of reproductive loss [N. To. Tetruashvili, A. A. Agadzhanova. The screening program and pregestational preparation of patients with habitual miscarriage (clinical lecture). - 2012. - №6. - S. 87-91; Sidelnikov Century Meters Miscarriage - a modern view on the problem // ROS. Vestn. akush.-gynecol. - 2007. No. 2. - S. 62-64]. So, from 15 to 25% of all reported pregnancies spontaneously abort, with 5-20% recurrent miscarriage (PPF), and 80% pregnancies terminate up to 12 weeks [D. Y. hayrapetov. Etiological factors of habitual miscarriage // Obstetrics and Gynecology. - 2011. No. 8. - S. 102-106; Baimuradov S. M. Pathogenesis, rincipa diagnostics, prevention and treatment of the syndrome of fetal loss due to acquired and genetic defects of hemostasis: dis. ... Prof. the honey. Sciences. - M., 2007. - 286 S.].
The causes of pregnancy loss, are extremely varied and include anatomical abnormalities, hormonal disorders, genetic/chromosomal defects, the pathology of hemostasis, Islamically failure, uterine cancer, congenital malformations, intrauterine synechia, endocrine and infectious disorders [B. I. Medvedev, E. E. Voropaeva, E. L. Kazachkov, E. A. Kazachkov. Extragenital diseases and social status of women with spontaneous abortion // Obstetrics and Gynecology. - 2012. - №4, 2. - S. 97-102; Tetruashvili N. To. Early pregnancy loss (immunological aspects, ways of prevention and treatment): dis. ... Prof. the honey. Sciences. - M., 2008. - 247 S.; Ivaschenko, I. E., Bespalova O. N., Tarasenko O. A., Swede N.Y. The genetic basis of susceptibility to obstetric and gynecological pathology / Molecular medicine. - 2007. No. 3. - S. 19-26; N. In. Dolgushin. Immunological aspects of the development of placental insufficiency and miscarriage in patients with chronic viral infections // Obstetrics and Gynecology. - 2008. No. 4. - S. 16-19]. Despite the fact that modern diagnostic capabilities allow with great accuracy to verify Ave is in the office of pregnancy loss, it is not always possible to achieve the desired result. Thus, the loss of a pregnancy in the early stages occupies an important place in the structure of the obstetric-gynecologic pathology, and continues to remain at a fairly high level [Sidelnikov Century Meters Miscarriage - modern look // Dr. Roux. - 2009. No. 6-1. - S. 42-46], which makes it necessary to search for new possible causes that affect the course of pregnancy in the early stages, and methods of early diagnosis. One of the reasons for the development of pregnancy loss is the disruption of the formation of connective tissue in the human body in the form of undifferentiated connective tissue dysplasia and, in particular, in the sex organs [Caurina T. I. Hereditary collagenoses. - SPb.: Nevsky dialect, 2000. - 272 S.; zemtsovsky E. C. dysplastic phenotypes. Dysplastic heart: analytical absor. - SPB.6 Olga, 2007. - 80 S.]. It is shown that the presence of undifferentiated connective tissue dysplasia in women is the main reason for the formation of the isthmic-cervical insufficiency in the late first and early second trimester of pregnancy, the formation of placental insufficiency, disorders of angiogenesis in the myometrium [Gurbanova S. R. the Role of undifferentiated connective tissue dysplasia in the pathogenesis of isthmic-cervical insufficiency // proceedings of the IX Sarossy the ski scientific. forum "Mother and Child". - M., 2007. - S. 121; Gazazian M., Characteristics of pregnancy and delivery in patients with connective tissue dysplasia. - 2007; L. M. Komissarov, A. N. Karachaevo, M. I. Kesava. During pregnancy and childbirth with connective tissue dysplasia // Obstetrics and gynecology. - 2012. No. 3. - S. 4-8; Starostin T. A., Lipman A. D., A. A. Y. Diagnostic value of blood flow in the uterine arteries and small arteries of the cervix with isthmic-cervical nedostatocnosti // Akush. and gin. - 1998. No. 2. - S. 15-17; Caurina T. I., Gorbunov Century. N. Connective tissue dysplasia. - SPb., 2009; D. Daskalakis, Papantoniou N, Mesogitis S, Antsaklis A. Management of cervical insufficiency and submissive fetal membranes // Obstet. Gynecol. - 2006. - Vol.107, No. 2. - P. 221-226]. At the same time during pregnancy to actively influence the formation of connective tissue is not possible. This makes it necessary to actively involve in the scheme pregravid and preconceptually preparations preparations ramblinrosie the formation of connective tissue, which are widely used in cardiology, pulmonology, internal medicine, Pediatrics [makatsariya A. D., Yudaeva HP Management of pregnancy and delivery in patients with mesenchymal dysplasia (syndrome, Marfan's syndrome, Ehlers-Dunloe, Rendu-Osler). M, 2005; Grachev, O. N. Connective tissue dysplasia prevention of gestational complications / Matters. gin., akush. and perinatal. - 010. No. 3. - S. 25-29; zemtsovsky E. C. Diagnosis and treatment of connective tissue dysplasia / Medical Bulletin. - 2006. №11 (354); Klimanov A. C., Tkachev O. N., Wertkin A. L. connective tissue Dysplasia and pregnancy (review) // Ter. Arch. - 2004. No. 11. - S. 80-83]. However, diagnosis of the presence NDCT represents certain difficulties due to the need of a large volume of research: the diagnosis is established by a combination of phenotypic characteristics that require costly, long period of examination and attraction of specialists of different profiles. In addition, until now, have not developed a unified classification, allowing vysokomehanizirovannoe to diagnose the presence of undifferentiated connective tissue dysplasia.
The main methods of diagnosis of undifferentiated connective tissue dysplasia are clinical when the diagnosis is established by a combination of phenotypic traits, such as asthenic body type, no stretch marks on the abdominal wall in women with a history of childbirth, violation of refraction at the age of 45, muscular hypotonia and low rates manometry, a tendency to easy bruising, bleeding in the postpartum period, vascular dysfunction, cardiac rhythm and conduction, EPI is ant, hypertelorism eyes, blue sclera, accrete lobe, the nasal septum, liver spots, anomaly bite anomaly teeth, scoliosis, kyphosis, kyphoscoliosis, flatfoot 2-3 degrees, elastosis of the skin, hypermodernity joints, prone to sprains, allergies and colds, varicose veins, hemorrhoids, biliary dyskinesia, a violation of the evacuation function of the gastrointestinal tract, the threat of premature birth at term 32-35 weeks of gestation, preterm delivery, fast rapid delivery history with hypotonic hemorrhage in the 3rd period of confinement or without genital prolapse, hernia, diverticula, dolichosigmoid, abnormalities in the platelet hemostasis. On the basis of these characteristics suggested several diagnostic protocols for verification of the diagnosis of undifferentiated connective tissue dysplasia (S. K. Yevtushenko, 2002; T. Y. Smolenova, 2003; T. I. Kaurinui, 2006; L. N. Fomin, 2000; So Milkowski-Dimitrova and A. Kartasheva, 1985). These methods are not sufficiently accurate due to the lack of standardization of the evaluation of detected features. Thus, the same patient may be attributed not only to different degrees of severity of undifferentiated connective tissue dysplasia, but not the diagnosis of undifferentiated connective tissue dysplasia which may be rejected. In addition, the classification So Milkowski-Dimitrova and A. Kartasheva (1985) limits us a number of secondary characteristics.
The main disadvantage of these methods of diagnosis NDCT is:
1) the inaccuracy of diagnosis,
2) lack of standardization in the objectification detected symptoms,
3) the large number of studies.
The proposed method for the diagnosis of NDCT, based on the determination of FA in biopsies of the endometrium, will eliminate the disadvantages of the above methods.
The solution of this problem is achieved by the fact that in women with recurrent pregnancy loss pregnancy history is taken PayPal endometrial biopsy on 23-26 day of the menstrual cycle. Preparing the sample - weight of 3 mg is Further defined fibrinolytic activity by the method of fibrin plates. The principle of the method is to visually check the degree of dissolution of fibrin clot prepared in the form of thin plates, put the investigated sample. If the latter (plasma, serum, tissue extract, serous fluid, etc.) has fibrinolytic activity, it creates around itself a zone of lysis, the area of which is proportional to this activity.
The progress of the operation.
I - preparation of a standard fibrin plates. In chemical glass gently mixing the season (avoid foam formation!) 9 ml of a solution of fibrinogen and 0.2 ml of thrombin. The mixture is immediately poured into a Petri dish with an inner diameter of 10 cm Light tilting the Cup to achieve a uniform distribution of liquid on its plane, after which the Cup is placed on a horizontal surface until complete coagulation of fibrinogen.
II - application of the material on record. The sample weight of 3 mg is applied parallel to the surface of the cold plate. Petri dishes are placed in a thermostat (37°° C) for 20 hours. After a specified period of time measured two mutually perpendicular diameters of each zone of lysis and calculated the areas of these zones.
III - evaluation of results. The size of the zone of lysis is directly proportional to the magnitude of the fibrinolytic activity of the investigated samples. And when indicators FA endometrium less than 23.5 mm2receives a diagnosis NDCT. In this way the surveyed 68 women. Of them women without NDCT - 25 women, their average FA was 61,0±4.8 mm2with fluctuations in individual performance from 23,55 to 94.2 mm2(PL.2), women with NDCT - 43 women, the average FA of 14.5±1.0 mm2with fluctuations in individual performance from 7,06 to 28.3 mm2(PL.1). Moreover, in the group of women with NDCT indicators FA endometrium was in the performance of the group of women without NDCT only are 11.62% of cases.
Thus, the claimed method surveyed 68 size is n, of them positive result was achieved in 63 patients, which is of 92.6% and allows the accuracy to diagnose NDCT in women with miscarriage in the early stages in history.
Previously fibrinolytic activity, the method fibrin plates were determined in the urine (Mingaleev E. I., 2006) for optimization of the method of local hemostasis.
The novelty of the proposed method lies in the fact that the first set of indicators fibrinolytic activity in the endometrium, and this index is first used to diagnose the presence of NDCT in women with pregnancy loss in the early stages in history.
Distinctive features of the process are: established diagnostic criteria for fibrinolytic activity of the endometrium in the range below 23,55 mm2.
The technical result of the provided method is that the tissue sample is determined fibrinolytic activity and when it is less 23,55 mm2diagnosed with undifferentiated connective tissue dysplasia.
Example No. 1. The patient Polina I. I., 37 years old, IB No. 881. Diagnosis: habitual miscarriage mixed Genesis. The patient was examined at the level of FA endometrium. Was the result - 9,42 mm2. When using classification So Milkowski-Dimitrova and A. Kartasheva(1985) and L. N. Fomin (2000) the patient has NDCT of the third degree. When using classification T. Y. Smolenova (2003) the patient has NDCT second severity. The diagnosis was confirmed (Table.1).
Example No. 2. Ivanova, E. S., 23 years old, IB No. 1017. Diagnosis: habitual miscarriage mixed Genesis. The patient was examined at the level of fibrinolytic activity of the endometrium. Was the result - 78.5 mm2. When assessing phenotypic signs of the patient was not identified NDCT none of the presented classificati: So Milkowski-Dimitrova and A. Kartasheva (1985), L. N. Fomin (2000), T. Y. Smolenova (2003) (Table.2).
|Data fibrinolytic activity of the endometrium in women without undifferentiated connective tissue dysplasia with the loss of a pregnancy in the early stages in history|
|F. Acting||IB||Diagnosis||Fibrinolytic activity|
|1. G-VA T. C.||957||Habitual miscarriage mixed Genesis||12,56 mm2|
|2. W-VA A. G.||826||Habitual miscarriage mixed Genesis||9,42 mm2|
|3. And O. G.||1393||Habitual miscarriage mixed Genesis||12,56 mm2|
|4. Islands E. C.||244||Habitual miscarriage mixed Genesis||15.7 mm2|
|5. S-VA N.N.||143||Habitual miscarriage mixed Genesis||19,62 mm2|
|6. E-VA N.N.||208||Habitual miscarriage mixed Genesis||15.7 mm2|
|7. B-UK N. In.||237||Habitual miscarriage mixed Genesis||of 28.26 mm2|
|8. X-WA O. I.||216||Habitual miscarriage mixed Genesis||,42 mm 2|
|9. F-VA E. Y.||336||Habitual miscarriage mixed Genesis||12,56 mm2|
|10. With-Kaya L. C.||336||Habitual miscarriage mixed Genesis||15.7 mm2|
|11. Peninsula E. K.||359||Habitual miscarriage mixed Genesis||of 28.26 mm2|
|12. X-WA So N.||769||Habitual miscarriage mixed Genesis||9,42 mm2|
|13. G-VA T. C.||436||Habitual miscarriage mixed Genesis||9,42 mm2|
|14. M-VA A. C.||373||Habitual miscarriage mixed Genesis||23,55 mm2|
|15. G-VA E. C.||495||Habitual miscarriage mixing the spent Genesis||23,55 mm2|
|16. H-VA M. I.||580||Habitual miscarriage mixed Genesis||9,42 mm2|
|17. M-Kai E. A.||611||Habitual miscarriage mixed Genesis||of 28.26 mm2|
|18. B-VA, M. P.||868||Habitual miscarriage mixed Genesis||9,42 mm2|
|19. C-ha T. N.||816||Habitual miscarriage mixed Genesis||12,56 mm2|
|20. K-VA A. Y.||874||Habitual miscarriage mixed Genesis||15.7 mm2|
|21. P-VA.||999||Habitual miscarriage mixed Genesis||7,06 mm2|
|22. With-I. N.||918||The usual is evansiana pregnancy mixed Genesis||15.7 mm2|
|23. M-VA A. N.||998||Habitual miscarriage mixed Genesis||7,06 mm2|
|24. P.-E. C.||881||Habitual miscarriage mixed Genesis||9,42 mm2|
|25. C-VA E. C.||923||Habitual miscarriage mixed Genesis||23,55 mm2|
|26. S-VA L. A.||517||Habitual miscarriage mixed Genesis||12,56 mm2|
|27. R-VA N. A.||146||Habitual miscarriage mixed Genesis||15.7 mm2|
|28. In-VA A. C.||1048||Habitual miscarriage mixed Genesis||7,06 mm2|
|29. W-A. B.||241||The usual n is the pregnancy mixed Genesis||9,42 mm2|
|30. U-VA P. F.||339||Habitual miscarriage mixed Genesis||12,56 mm2|
|31. B-VA N. And||383||Habitual miscarriage mixed Genesis||9,42 mm2|
|32. E-O. R.||368||Habitual miscarriage mixed Genesis||23,55 mm|
|33. W-VA S. C.||438||Habitual miscarriage mixed Genesis||7,065 mm2|
|34. S-VA M. A.||490||Habitual miscarriage mixed Genesis||23,55 mm2|
|35. K-on A. C.||469||Habitual miscarriage mixed Genesis||of 28.26 mm2|
|36. H-VA L N.||577||Familiar Nevins the of pregnancy mixed Genesis||9,42 mm2|
|37. P-Ko A. C.||AMB.||Habitual miscarriage mixed Genesis||12,56 mm2|
|38. W-WA M N.||AMB.||Habitual miscarriage mixed Genesis||15.7 mm2|
|39. F-VA S. C.||AMB.||Habitual miscarriage mixed Genesis||15.7 mm2|
|40. O-to N.In.||875||Habitual miscarriage mixed Genesis||12,56 mm2|
|41. B-BA, N.||909||Habitual miscarriage mixed Genesis||7,06 mm2|
|42. G-VA O. C.||884||Habitual miscarriage mixed Genesis||9,42 mm2|
|43. P-||1097||Habitually the miscarriage mixed Genesis||9,42 mm2|
|Data fibrinolytic activity of the endometrium in women with undifferentiated connective tissue dysplasia with the loss of a pregnancy in the early stages in history|
|F. Acting||IB||Diagnosis||Fibrinolytic activity|
|1. C-VA E. M.||1495||Habitual miscarriage mixed Genesis||78.5 mm2|
|2. T-VA S. C.||1209||Habitual miscarriage mixed Genesis||56,52 mm2|
|3. G-VA M. S.||230||Habitual miscarriage mixed Genesis||of 28.26 mm2|
|4. K-VA K. E.||205||Habitual miscarriage mixed Genesis||50,24 mm2|
|5. K-VA I. C.||226||Habitual miscarriage mixed Genesis||23.5 mm2|
|6. C-WA Y. Y.||401||Habitual miscarriage mixed Genesis||23.5 mm2|
|7. Peninsula A. A.||389||Habitual miscarriage mixed Genesis||23.5 mm2|
|8. H-E. A.||531||Habitual miscarriage mixed Genesis||32,97 mm2|
|9. Peninsula A. A.||437||Habitual miscarriage mixed Genesis||77,71 mm2|
|10. H-e O. C.||514||Habitual miscarriage mixed Genesis||50,24 mm2|
|11. And-VA M. H.||436||Habitual miscarriage mixed Genesis||12. K-VA I. M.||585||Habitual miscarriage mixed Genesis||of 28.26 mm2|
|13. B-C. S.||554||Habitual miscarriage mixed Genesis||78.5 mm2|
|14. L-VA N. In.||540||Habitual miscarriage mixed Genesis||63,58 mm2|
|15. S-VA N.And.||568||Habitual miscarriage mixed Genesis||56,52 mm2|
|16. S-VA N.A.||709||Habitual miscarriage mixed Genesis||70,65 mm2|
|17. K-VA O. N.||581||Habitual miscarriage mixed Genesis||63,58 mm2|
|18. C-VA S. A.||578||Habitual miscarriage of beremend the STI mixed Genesis||a 94.2 mm2|
|19. S-VA E. C.||1498||Habitual miscarriage mixed Genesis||a 94.2 mm2|
|20. K-VA C. N.||763||Habitual miscarriage mixed Genesis||78.5 mm2|
|21. D-VA A. S.||760||Habitual miscarriage mixed Genesis||a 94.2 mm2|
|22. K-VA L. N.||764||Habitual miscarriage mixed Genesis||a 94.2 mm2|
|23. H-VA E. A.||804||Habitual miscarriage mixed Genesis||78.5 mm2|
|24. And society E. S.||1017||Habitual miscarriage mixed Genesis||78.5 mm2|
|25 .K-on E. I.||1151||Habitually the miscarriage mixed Genesis||56,52 mm2|
Method for the diagnosis of undifferentiated connective tissue dysplasia in women with pregnancy loss early in history by examining biopsies of the endometrium, characterized in that the tissue sample is determined fibrinolytic activity and when it is less 23,55 mm2diagnosed with undifferentiated connective tissue dysplasia.
SUBSTANCE: instrument comprises an oral sample collection vessel, a detector able to detect a marker in this sample, an indicator actuated by a detector signal. The above vessel is detachably connected to an oral cavity instrument. The vessel comprises a sample collection element, a sample storage container, and a passage connecting the collection element and the container to supply the sample to the container by capillary action. The indicator is integrated into the container. The declared instrument is used to diagnose oral diseases by collecting the oral sample, detecting one or more markers in this sample and indicating the presence of one of the disease markers.
EFFECT: inventions enables establishing an accurate and fast diagnosis of the oral pathologies accompanying the daily oral care by placing the detector inside the container able to accumulate a required amount of the sample to be diagnosed.
25 cl, 1 dwg
SUBSTANCE: technique involves the clinical-laboratory examination of a sportsman who completed heavy physical activity 12-16 hours ago. The examination extent is determined taking into account the organs and systems most vulnerable to the physical activity while deriving the prognostically significant criteria of the morphofunctional body state. The examination involves measuring and analyzing the biochemical, haematological, immunological and functional values, as well as vitamin-mineral saturation. And if the above values are stably unchanged, reliably different from the norm, nonspecific changes of the sportsman's organs and systems are diagnosed.
EFFECT: technique provides the early diagnosis of the significant changes of the organs and systems during trainings and competitions that enables taking further timely measures to prevent the further progression of pathological conditions and maintaining thereby occupational performance and achieving stable high sport results.
SUBSTANCE: efficiency of treatment of patients with high grade non-Hodgkin malignant lymphoma is determined by the likelihood of achieving remission, and 5-year total and relapse-free survival. The method comprises the study of polymorphism G13494A 6th intron of gene TP53 of the patient. In case of revealing in the patient of homozygous genotype G/G in a given locus the low efficiency of treatment is predicted, namely, low likelihood of 5-year survival of the patient and low likelihood of absence of relapse. In the case of revealing in the patient of the genotype A/A or G/A in a given locus, the high efficiency of treatment is predicted, namely the high likelihood of remission and 5-year survival of patient.
EFFECT: invention enables to assess the efficiency of treatment of patients with high grade non-Hodgkin malignant lymphoma on the degree of polymorphism G13494A of 6th intron of gene TP53.
5 dwg, 10 tbl, 2 ex
SUBSTANCE: invention represents a diagnostic technique for the disturbed thrombocyte aggregation accompanying mucoviscidosis in children involving a thrombocyte aggregation test using the Multiplate aggregometer inducers. Trays with a magnetic mixer and electrodes are added with NaCl 400 mcl at 37°C and immediately added with whole blood 400 mcl from a hirudin test tube, incubated in the chamber for two minutes; the tray is added with 30 mcl of an aggregation inducer specified in a group: soluble thrombin receptor - peptid-6, adenosine diphosphate, arachidonic acid. The thrombocyte aggregation rate is displayed on the screen in the form of a curve, and the sub-curve area U is automatically calculated; the sub-curve area U shows the thrombocyte aggregation state as compared to reference values in the group of healthy children; if the threshold area U has appeared to exceed the reference, the thrombocyte hyperaggregation, while the threshold area U being less than the reference, the thrombocyte hypoaggregation is stated.
EFFECT: invention provides the timely diagnosis of microcirculatory disorders accompanying mucoviscidosis.
2 ex, 1 dwg
SUBSTANCE: invention relates to the field of microbiology, namely to a method of microorganism characteristic. The essence of the method consists in the following: (a) obtaining a sample to be tested, about which it is known that it contains or can contain microorganisms; (b) layering the tested sample on a density buffer in a container, where the said density buffer possesses a uniform density from approximately 1.025 to approximately 1.120 g/ml; (c) addition of an identifier into the said tested sample and/or into the said density buffer; (d) centrifugation of the said container in order to separate microorganisms from other components of the said tested sample and to form a deposit of microorganisms; (e) spectroscopic analysis of the deposit and/or the said one or more than one identifier with obtaining measurements, which characterise the microorganisms, where the said spectroscopic analysis is carried out when the said deposit is located in the said container; and (f) characteristic of the microorganisms in the deposit on the basis of the obtained measurements and/or the presence or absence of the said identifier or a metabolised form of the said identifier in the deposit, where the said microorganisms are characterised by one or more classification models, selected from the group, consisting of Gram groups, clinical Gram groups, therapeutic and functional groups.
EFFECT: application of the claimed invention makes it possible to increase the accuracy of the microorganism characteristic.
15 cl, 5 dwg, 1 tbl, 4 ex
SUBSTANCE: invention refers to medicine, namely to qualitative differential instant diagnostic technique for benign and malignant periglottis new growths as shown by oral fluid biomarkers. Substance of the method consists in measuring a quantity of matrix metalloproteinase 2 (MMP 2) in patient's oral fluid; the clinical reference is the level of 1.7-2.9 ng/ml; if the MMP 2 content is 14.4-24.3 ng/ml, patient's periglottis papilloma is diagnosed; if the patient's oral fluid MMP 2 content is 4.1-6.8 ng/ml, periglottis cancer is diagnosed. A biomarker for the qualitative differential instant diagnosis of the periglottis new growths is a tissue inhibitor of metalloproteinase 2 (TIMP 2); the clinical reference is a level of 6.44-11.23 ng/ml; if the TIMP 2 content 29.25-48.75 ng/ml, patient's periglottis papilloma is diagnosed; the TIMP 2 content being 57.23-95.03 ng/ml, periglottis cancer is diagnosed.
EFFECT: using the declared technique enables providing more accurate differential diagnosis of the benign and malignant periglottis new growths.
2 cl, 6 ex
SUBSTANCE: method is implemented by preparing an incubation solution No.1 containing sulphanilic acid 500 mg in 1 M HCl 50 ml, and solution No.2 consisting of NaNO2 125 ml in distilled water 2.5 ml. Each solution is taken in an amount of 1 ml, mixed in a test tube and added with whole blood with a coagulate 200 mcl. The reaction is carried out for 10 min at a room temperature, and a drop of the suspension is used to produce a multilayer smear on a slide, dried and studied by computed cytophotometry.
EFFECT: more accurate determination.
SUBSTANCE: invention refers to medicine, namely diagnostics and can be used for assessing threatened foetal death following the aggravated cytomegalovirus infection at the early stages of gestation. To this effect, with the underlying cytomegalovirus infection, peripheral blood of a pregnant woman is analysed to measure the anti-cytomegalovirus IgG antibody titre and progesterone level. If the anti-cytomegalovirus IgG titre is 1:1600, and the progesterone level is 18.5±0.8 nmole/l, a threatened spontaneous miscarriage is stated.
EFFECT: method enables stating the threatened spontaneous miscarriage if any at the early stages of gestation.
SUBSTANCE: invention refers to medicine, and represents a method for the prediction of a risk of congenital infections by measuring specific Ig M and Ig G antibodies in a biological material, differing by the fact that the biological material is presented by the first-screening cervical smear at the 12th week of gestation; the smears are tested for the IgG antibodies to the rubella virus, cytomegalovirus, B19V parvovirus, toxoplasm viruses, type 1 and 2 herpes simplex viruses and an avidity of the specific Ig G to this agents; additionally, the same smear is tested for secretory non-specific Ig A by IFA to cytomegalovirus, Chlamydia, Mycoplasm antigens, and a genetic material of this microorganisms by PCR, and depending on the findings, groups of a high, moderate and low risk of congenital infections are predicted.
EFFECT: invention provides the more accurate prediction of the risk of the most actual congenital infections by the integral assessment of a collection of clinical anamnestic data, and the qualitative parameters of the laboratory findings at the first pregnancy screening.
SUBSTANCE: invention aims at assessing an efficacy of therapeutic agents (TA) for improving individual's cognitive functions. The patient's blood serum is examined for the HLDF protein, titres of idiotypic and anti-idiotypic HLDF antibodies before and after the TA is administered, and the above derived data are used to calculate MMSE before and after the TA is administered by formula; the derived MMSEs are compared, and the TA efficacy is assessed by the comparison result.
EFFECT: invention enables more real-time selection of one or another TA or the length of the course of administration, including the real-time prescription of this course if the patient's condition deteriorates.
3 tbl, 2 ex
FIELD: medicine, hepatology.
SUBSTANCE: one should detect the level of hepato-specific enzymes (HSE) in blood plasma, such as: urokinase (UK), histidase (HIS), fructose-1-phosphataldolase (F-1-P), serine dehydratase (L-SD), threonine dehydratase (L-TD) and products of lipid peroxidation (LP), such as: dienic conjugates (DC), malonic dialdehyde (MDA). Moreover, one should detect the state of inspecific immunity parameters, such as: immunoregulatory index (IRI) as the ratio of T-helpers and T-suppressors, circulating immune complexes (CIC). Additionally, one should evaluate the state of regional circulation by applying rheohepatography (RHG), the system of microhemocirculation with the help of conjunctival biomicroscopy (CB) to detect intravascular index (II). In case of increased UK, HIS levels up to 0.5 mcM/ml/h, F-1-P, L-SD, L-Td, LP products, CIC by 1.5 times, higher IRI up to 2 at the norm being 1.0-1.5, altered values of regional circulation, increased II up to 2 points at the norm being 1 point, not more one should diagnose light degree of process flow. At increased level of UK, HIS up to 0.75 mcM/ml/h, F-1-P, L-SD, L-TD, LP products, CIC by 1.5-2 times, increased IRI up to 2.5, altered values of regional circulation, increased II up to 3-4 points one should diagnose average degree of process flow. At increased level of UK, HIS being above 0.75 mcM/ml/h, F-1-P, L-SD, L-TD, LP products, CIC by 2 and more times, increased IRI being above 2.5, altered values of regional circulation, increased II up to 5 points and more one should diagnose severe degree of process flow.
EFFECT: higher accuracy of diagnostics.
FIELD: medicine, infectology, hepatology.
SUBSTANCE: in hepatic bioptate one should detect products of lipid peroxidation (LP), such as: dienic conjugates (DC), activity of antioxidant enzymes, such as: catalase (CAT)and superoxide dismutase (SOD). One should calculate by the following formula: C = DC/(SOD x CAT)x100, where DC - the content of dienic conjugates, SOD - activity of superoxide dismutase, CAT - activity of catalase. At coefficient (C) values being above 65 one should predict high possibility for appearance of cirrhosis, at 46-645 - moderate possibility and at 14-45 -low possibility for appearance of cirrhosis.
EFFECT: higher accuracy of prediction.
FIELD: medicine, clinical toxicology.
SUBSTANCE: at patient's hospitalization one should gather the data of clinical and laboratory values: on the type of chemical substance, patient's age, data of clinical survey and laboratory values: body temperature, the presence or absence of dysphonia, oliguria being below 30 ml/h, hemoglobinuria, erythrocytic hemolysis, exotoxic shock, glucose level in blood, fibrinogen and creatinine concentration in blood serum, general bilirubin, prothrombin index (PTI), Ph-plasma, the state of blood clotting system. The state of every sign should be evaluated in points to be then summed up and at exceeding the sum of points being above "+20" one should predict unfavorable result. At the sum of "-13" prediction should be stated upon as favorable and at "-13" up to "+20" - prediction is considered to be doubtful.
EFFECT: higher accuracy of prediction.
2 ex, 3 tbl
FIELD: medicine, juvenile clinical nephrology.
SUBSTANCE: disease duration in case of obstructive pyelonephritis should be detected by two ways: either by detecting the value of NADPH-diaphorase activity, as the marker of nitroxide synthase activity in different renal department and comparing it to established norm, or by detecting clinico-laboratory values, such as: hemoglobin, leukocytes, eosinophils, urea, beta-lipoproteides, lymphocytes, neutrophils, the level of glomerular filtration, that of canalicular reabsorption, urinary specific weight, daily excretion of oxalates, arterial pressure, and estimating their deviation against average statistical values by taking into account a child's age.
EFFECT: higher efficiency of detection.
7 dwg, 1 ex, 6 tbl
FIELD: clinical medicine, pulmonology.
SUBSTANCE: one should carry out complex estimation of interleukin-1β) concentration in blood, saliva, bronchoalveolar liquid. Moreover, one should detect distribution coefficient (DC) for IL-1β as the ratio of IL-1β blood content to IL-1β salivary content. At increased IL-1β blood content by 10 times and more, by 2 times in saliva, unchanged level of bronchoalveolar IL-1β, at DC for IL-1β being above 1.0 one should predict bronchial obstruction. The method enables to conduct diagnostics of the above-mentioned disease at its earlier stages.
EFFECT: higher efficiency of prediction.
FIELD: medicine, diagnostics.
SUBSTANCE: the present innovation deals with genetic trials, with diagnostic field of oncological diseases due to analyzing DNA by altered status of gene methylation that take part in intracellular regulation of division, differentiating, apoptosis and detoxication processes. One should measure the status of methylation in three genes: p16, E-cadherine and GSTP1 in any human biological samples taken out of blood plasma, urine, lymph nodes, tumor tissue, inter-tissue liquid, ascitic liquid, blood cells and buccal epithelium and other; one should analyze DNA in which modified genes of tumor origin or their components are present that contain defective genes, moreover, analysis should be performed due to extracting and purifying DNA out of biological samples followed by bisulfite treatment of this DNA for modifying unprotected cytosine foundations at keeping 5-methyl cytosine being a protected cytosine foundation followed by PCR assay of bisulfite-treated and bisulfite-untreated genes under investigation and at detecting alterations obtained according to electrophoretic result of PCR amplificates, due to detecting the difference in the number and electrophoretic mobility of corresponding fractions at comparing with control methylated and unmethylated samples containing normal and hypermethylated forms of genes one should diagnose oncological diseases. The method provides higher reliability in detecting tumors, detection of remained tumor cells after operation.
EFFECT: higher efficiency of therapy.
1 cl, 3 dwg, 4 ex
FIELD: medicine, gastroenterology.
SUBSTANCE: one should carry out diagnostic studying, moreover, on the 5th -6th d against the onset of exacerbation in case of gastric and duodenal ulcerous disease one should detect the content serotonin, histamine and acetylcholine in blood, then during 2-3 wk one should conduct medicinal therapy to detect serotonin, histamine and acetylcholine level in blood again and at serotonin content being by 2-3 times above the norm, histamine - by 1.15-1.4 times above the norm and acetylcholine - by 20-45% being below the norm one should predict the flow of gastric and duodenal ulcerous disease as a non-scarring ulcer.
EFFECT: higher accuracy of prediction.
SUBSTANCE: method involves taking blood from ulnar vein (systemic blood circulation) and from large vein of the injured extremity proximal with respect to lesion focus (regional blood circulation). Spontaneous NST-test value is determined and difference is calculated in systemic and regional blood circulation as regional-to-systemic difference. The difference value is used for predicting clinical course of pyo-inflammatory disease in extremities.
EFFECT: high accuracy of diagnosis.
4 cl, 2 tbl
FIELD: medicine, gastroenterology.
SUBSTANCE: one should introduce biologically active substance, moreover, in patient's blood serum one should detect the content of acetyl choline and choline esterase activity followed by 2-h-long intragastric pH-metry at loading with biologically active substance as warm 40-45%-honey water solution at 35-40 C, and at increased content of acetyl choline being above 1.0 mM/l, choline esterase being above 0.5 mM/l/30 min and pH level being 6.0-6.9 it is possible to consider apitherapy to be useful for treating ulcerous duodenal disease.
EFFECT: higher efficiency and accuracy of detection.
FIELD: medicine, gastroenterology.
SUBSTANCE: it has been suggested a new method to detect pharmacological sensitivity to preparations as acidosuppressors. After the intake of the preparation a patient should undergo fibrogastroduodenoscopy 3 h later, then, through endoscopic catheter one should introduce 0.3%-Congo red solution intragastrically and the test is considered to be positive at keeping red color that indicates good sensitivity to the given preparation, and in case of dark-blue or black color the test is considered to be negative that indicates resistance to this preparation. The suggested innovation widens the number of diagnostic techniques of mentioned indication.
EFFECT: higher efficiency of diagnostics.